On August 21, 2025, Ionis Pharmaceuticals announced the FDA approval of DAWNZERA™ (donidalorsen) for preventing hereditary angioedema attacks in patients aged 12 and older. This approval is significant as DAWNZERA is the first RNA-targeted treatment for this condition, showing an 81% reduction in monthly attack rates in clinical trials.